Standardising policy and technology responses in the immediate aftermath of a pandemic: a comparative and conceptual framework.

Publisher: BioMed Central Country of Publication: England NLM ID: 101170481 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-4505 (Electronic) Linking ISSN: 14784505 NLM ISO Abbreviation: Health Res Policy Syst Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2003-

COVID-19*/epidemiology; Humans ; SARS-CoV-2 ; Pandemics/prevention & control ; Policy ; Disease Outbreaks

Background: The initial policy response to the COVID-19 pandemic has differed widely across countries. Such variability in government interventions has made it difficult for policymakers and health research systems to compare what has happened and the effectiveness of interventions across nations. Timely information and analysis are crucial to addressing the lag between the pandemic and government responses to implement targeted interventions to alleviate the impact of the pandemic.
Methods: To examine the effect government interventions and technological responses have on epidemiological and economic outcomes, this policy paper proposes a conceptual framework that provides a qualitative taxonomy of government policy directives implemented in the immediate aftermath of a pandemic announcement and before vaccines are implementable. This framework assigns a gradient indicating the intensity and extent of the policy measures and applies the gradient to four countries that share similar institutional features but different COVID-19 experiences: Italy, New Zealand, the United Kingdom and the United States of America.
Results: Using the categorisation framework allows qualitative information to be presented, and more specifically the gradient can show the dynamic impact of policy interventions on specific outcomes. We have observed that the policy categorisation described here can be used by decision-makers to examine the impacts of major viral outbreaks such as SARS-CoV-2 on health and economic outcomes over time. The framework allows for a visualisation of the frequency and comparison of dominant policies and provides a conceptual tool to assess how dominant interventions (and innovations) affect different sets of health and non-health related outcomes during the response phase to the pandemic.
Conclusions: Policymakers and health researchers should converge toward an optimal set of policy interventions to minimize the costs of the pandemic (i.e., health and economic), and facilitate coordination across governance levels before effective vaccines are produced. The proposed framework provides a useful tool to direct health research system resources and build a policy benchmark for future viral outbreaks where vaccines are not readily available.
(© 2023. The Author(s).)

BMJ Glob Health. 2021 Dec;6(12):. (PMID: 34857521)
Science. 2020 May 1;368(6490):489-493. (PMID: 32179701)
Health Aff (Millwood). 2007 Jul-Aug;26(4):1069-77. (PMID: 17630449)
Public Adm Rev. 2020 Jul-Aug;80(4):595-602. (PMID: 32836439)
J Travel Med. 2020 Mar 13;27(2):. (PMID: 32052846)
Environ Sci Technol. 2020 Apr 7;54(7):3733-3735. (PMID: 32202421)
Health Res Policy Syst. 2022 Mar 2;20(1):25. (PMID: 35236369)
PLoS Comput Biol. 2011 Feb 10;7(2):e1001076. (PMID: 21347316)
Ann Intern Med. 2009 Oct 6;151(7):437-46. (PMID: 19652172)
Bull Math Biol. 2020 Apr 8;82(4):52. (PMID: 32270376)
Public Adm Rev. 2020 Jul-Aug;80(4):644-650. (PMID: 32836444)
Nature. 2020 Sep 29;:. (PMID: 32994583)
Sci Data. 2020 Aug 27;7(1):285. (PMID: 32855430)
Clin Infect Dis. 2010 Jan 15;50(2):165-74. (PMID: 20021259)
Health Policy Technol. 2020 Dec;9(4):673-691. (PMID: 32874853)
Health Policy Technol. 2020 Dec;9(4):510-524. (PMID: 32874858)
Health Policy Technol. 2020 Dec;9(4):525-559. (PMID: 32874863)
Health Policy Technol. 2020 Dec;9(4):454-487. (PMID: 32895626)
Public Adm Rev. 2020 Sep-Oct;80(5):862-865. (PMID: 32836454)
Curr Pharmacol Rep. 2020;6(3):56-70. (PMID: 32395418)
Lancet. 2020 Mar 21;395(10228):931-934. (PMID: 32164834)
Proc Biol Sci. 2003 Dec 22;270(1533):2565-71. (PMID: 14728778)
Front Microbiol. 2020 Jul 14;11:1526. (PMID: 32760367)
Nat Hum Behav. 2021 Apr;5(4):529-538. (PMID: 33686204)
Clin Infect Dis. 2020 Jul 28;71(15):858-860. (PMID: 32166318)
Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S8-12. (PMID: 21342904)
PLoS One. 2007 May 02;2(5):e401. (PMID: 17476323)
JAMA. 2020 Jun 2;323(21):2129-2130. (PMID: 32324202)
Gastrointest Endosc. 2022 Nov;96(5):735-742.e3. (PMID: 35690149)
Lancet. 2020 Apr 18;395(10232):1255-1256. (PMID: 32247323)
Public Adm. 2022 Jun;100(2):356-374. (PMID: 33821039)
Lancet. 2020 Nov 7;396(10261):1525-1534. (PMID: 32979936)
Tour Manag. 2008 Oct;29(5):917-928. (PMID: 32287724)
Nat Biotechnol. 2020 May;38(5):515-518. (PMID: 32203294)
Public Adm Rev. 2020 Sep-Oct;80(5):765-773. (PMID: 32836443)
Lancet Infect Dis. 2009 Aug;9(8):473-81. (PMID: 19628172)
J Epidemiol Glob Health. 2011 Dec;1(1):33-60. (PMID: 23856374)
Risk Anal. 2017 Jan;37(1):4-19. (PMID: 27214756)
Health Policy Technol. 2020 Dec;9(4):623-638. (PMID: 32874854)
Influenza Other Respir Viruses. 2013 Nov;7(6):1103-12. (PMID: 23829670)
Sci Data. 2020 Aug 27;7(1):286. (PMID: 32855428)

Keywords: COVID-19; Economic outcomes; Health outcomes; Health research systems; Policy categorisation; Policy gradient; Policy interventions; Public health crisis

Date Created: 20230125 Date Completed: 20230127 Latest Revision: 20230202

20231215

PMC9875766

10.1186/s12961-022-00951-x

36698139